Ocular Therapeutix Inc (OCUL)

Ocular Therapeutix, Inc.'s stock price has been impacted by several events in the past six months. The company reported mixed Q4 2025 earnings, beating EPS estimates but missing revenue forecasts, and similar results in Q3 2025. An accelerated AXPAXLI timeline led to a significant stock gain. The company completed an equity financing to support operations into 2028. Inducement awards were granted to new employees. There was insider selling to cover taxes. The stock's 52-week high was $16.44 and its 52-week low was $5.79, with a closing price of $8.91 as of February 5, 2026.

There is no explicit information indicating significant demand seasonality for Ocular Therapeutix's products and services. Revenue fluctuations are attributed to reimbursement challenges rather than seasonal variations.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases and conditions, utilizing its ELUTYX technology to deliver therapeutic agents. The company operates within the biopharmaceutical sector and ophthalmic therapies industry, focusing on treatments for conditions like wet AMD, diabetic retinopathy, and dry eye disease. Key products and pipeline include DEXTENZA, AXPAXLI (OTX-TKI), OTX-DED, OTX-CSI, and PAXTRAVA (OTX-TIC).

Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts, United States. The company has a strategic partnership with AffaMed Therapeutics Limited for development and commercialization in Asia, indicating an expanding international presence.

Ocular Therapeutix generally holds a positive brand reputation within the analyst community, with a consensus rating of "Moderate Buy". The company's ELUTYX technology is considered a cornerstone of its strength. However, the company has faced financial losses and decreasing revenue, DEXTENZA reimbursement challenges, and market competition and financial pressures.

Ocular Therapeutix, Inc. has significant institutional ownership, with approximately 59% to 80.30% of the stock held by institutional investors. Individual insider ownership accounts for about 2.30% of the stock. The general public owns approximately 12% of the company, and private equity firms hold a 17% stake.